• Drug: Tremfya (guselkumab)

  • Manufacturer: Johnson & Johnson

  • Route of Administration: Intravenous, Subcutaneous

  • Site of Care: Outpatient
  • Approved Indication:

    • treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy
    • treatment of active psoriatic arthritis in adults
    • treatment of moderately-to-severely active Crohn’s disease in adults
    • treatment of moderately-to-severely active ulcerative colitis in adults

  • Disease: Crohn’s disease, plaque psoriasis, psoriatic arthritis, ulcerative colitis

  • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology

  • Enrollment Form Link: Enrollment Form

  • Phone Number: 844-4withMe (844-494-8463)

  • Fax Number: 800-600-7226

  • Product Website: tremfya.com